# Efficacy/Safety Study of Brisdelle™ (Formerly Known as Mesafem) in the Treatment of Vasomotor Symptoms (VMS)

> **NCT01361308** · PHASE3 · COMPLETED · sponsor: **Noven Therapeutics** · enrollment: 614 (actual)

## Conditions studied

- Postmenopausal Symptoms

## Interventions

- **DRUG:** Brisdelle (paroxetine mesylate)
- **DRUG:** Placebo capsules

## Key facts

- **NCT ID:** NCT01361308
- **Lead sponsor:** Noven Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-05
- **Primary completion:** 2011-12
- **Final completion:** 2012-02
- **Target enrollment:** 614 (ACTUAL)
- **Last updated:** 2015-10-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01361308

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01361308, "Efficacy/Safety Study of Brisdelle™ (Formerly Known as Mesafem) in the Treatment of Vasomotor Symptoms (VMS)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01361308. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*